Related Experiment Video
Updated: Sep 22, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Simple method for assessment of activities of thrombin inhibitors through their molecular structure parameters
Mohammad Hossein Keshavarz1, Zeinab Shirazi1, Mahdi Mohajeri1
1Faculty of Applied Sciences, Malek Ashtar University of Technology, Iran.
Abstract:
Thrombi (blood clots) form in blood vessels in thromboembolic disorders, which are among the main reasons for death in the world. A novel approach is presented to predict thrombin inhibitory activities ((log(103/Ki) (nM)) of some classes of non-peptidic thrombin inhibitors. The largest reported data set of log(103/Ki) for 260 thrombin inhibitors are used to derive and test the new model where it can be easily applied through a computer code. The new model is derived and tested based on 201 and 59 experimental data, respectively, where its reliability is established by external and internal validations. The reliability of the novel correlation is compared with the complex 3D-QSAR method CoMSIA based on donor hydrogen bond, electrostatic interactions, steric occupancy, local hydrophobicity, and acceptor hydrogen bond fields. The values of correlation coefficient (R2), and root mean squared error (RMSE) for 138/34 data of training/test sets, where the predicted results of complex CoMSIA calculations were available, are 0.9173/0.6010 (R2), and 0.2503/0.4911 (RMSE) as well as 0.8753/0.3888 (R2), and 0.3287/0.6358 (RMSE) for the new and CoMSIA models, respectively. Further statistical parameters also confirm high reliability, precision, accuracy, and the goodness-of-fit of the simple model.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

